Martin A S Meyer1, Sisse R Ostrowski, Anders Overgaard, Matthew S Ganio, Niels H Secher, Craig G Crandall, Pär I Johansson. 1. Section for Transfusion Medicine, Capital Regional Blood Bank, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark; Center for Translational Injury Research, Department of Surgery, University of Texas Health Science Center at Houston, Houston, Texas. Electronic address: martin.as.meyer@gmail.com.
Abstract
BACKGROUND: Coagulation abnormalities contribute to poor outcomes in critically ill patients. In trauma patients exposed to a hot environment, a systemic inflammatory response syndrome, elevated body temperature, and reduced central blood volume occur in parallel with changes in hemostasis and endothelial damage. The objective of this study was to evaluate whether experimentally elevated body temperature and reduced central blood volume (CBV) per se affects hemostasis and endothelial activation. METHODS: Eleven healthy volunteers were subjected to heat stress, sufficient to elevate core temperature, and progressive reductions in CBV by lower body negative pressure (LBNP). Changes in hemostasis were evaluated by whole blood haemostatic assays, standard hematologic tests and by plasma biomarkers of coagulation and endothelial activation/disruption. RESULTS: Elevated body temperature and decreased CBV resulted in coagulation activation evidenced by shortened activated partial tromboplastin time (-9% [IQR -7; -4]), thrombelastography: reduced reaction time (-15% [-24; -4]) and increased maximum amplitude (+4% (2; 6)), all P < 0.05. Increased fibrinolysis was documented by elevation of D-dimer (+53% (12; 59), P = 0.016). Plasma adrenaline and noradrenaline increased 198% (83; 346) and 234% (174; 363) respectively (P = 0.006 and P = 0.003). CONCLUSIONS: This experiment revealed emerging hypercoagulability in response to elevated body temperature and decreased CBV, whereas no effect on the endothelium was observed. We hypothesize that elevated body temperature and reduced CBV contributes to hypercoagulability, possibly due to moderate sympathetic activation, in critically ill patients and speculate that normalization of body temperature and CBV may attenuate this hypercoagulable response.
BACKGROUND:Coagulation abnormalities contribute to poor outcomes in critically illpatients. In traumapatients exposed to a hot environment, a systemic inflammatory response syndrome, elevated body temperature, and reduced central blood volume occur in parallel with changes in hemostasis and endothelial damage. The objective of this study was to evaluate whether experimentally elevated body temperature and reduced central blood volume (CBV) per se affects hemostasis and endothelial activation. METHODS: Eleven healthy volunteers were subjected to heat stress, sufficient to elevate core temperature, and progressive reductions in CBV by lower body negative pressure (LBNP). Changes in hemostasis were evaluated by whole blood haemostatic assays, standard hematologic tests and by plasma biomarkers of coagulation and endothelial activation/disruption. RESULTS: Elevated body temperature and decreased CBV resulted in coagulation activation evidenced by shortened activated partial tromboplastin time (-9% [IQR -7; -4]), thrombelastography: reduced reaction time (-15% [-24; -4]) and increased maximum amplitude (+4% (2; 6)), all P < 0.05. Increased fibrinolysis was documented by elevation of D-dimer (+53% (12; 59), P = 0.016). Plasma adrenaline and noradrenaline increased 198% (83; 346) and 234% (174; 363) respectively (P = 0.006 and P = 0.003). CONCLUSIONS: This experiment revealed emerging hypercoagulability in response to elevated body temperature and decreased CBV, whereas no effect on the endothelium was observed. We hypothesize that elevated body temperature and reduced CBV contributes to hypercoagulability, possibly due to moderate sympathetic activation, in critically illpatients and speculate that normalization of body temperature and CBV may attenuate this hypercoagulable response.
Authors: Gustav Folmer Genét; Sisse Rye Ostrowski; Anne Marie Sørensen; Pär Ingemar Johansson Journal: Clin Appl Thromb Hemost Date: 2012-01-31 Impact factor: 2.389
Authors: Sietze Reitsma; Dick W Slaaf; Hans Vink; Marc A M J van Zandvoort; Mirjam G A oude Egbrink Journal: Pflugers Arch Date: 2007-01-26 Impact factor: 3.657
Authors: M Zaar; P I Johansson; L B Nielsen; C G Crandall; M Shibasaki; L Hilsted; N H Secher Journal: Clin Physiol Funct Imaging Date: 2009-07-28 Impact factor: 2.273
Authors: Matthew A Borgman; Morten Zaar; James K Aden; Zachary J Schlader; Daniel Gagnon; Eric Rivas; Jena Kern; Natalie J Koons; Victor A Convertino; Andrew P Cap; Craig Crandall Journal: Am J Physiol Regul Integr Comp Physiol Date: 2018-09-19 Impact factor: 3.619
Authors: Brian R Kupchak; Amy L McKenzie; Hui-Ying Luk; Cathy Saenz; Laura J Kunces; Lindsay A Ellis; Jakob L Vingren; Elaine C Lee; Kevin D Ballard; Evan C Johnson; Stavros A Kavouras; Matthew S Ganio; Jonathon E Wingo; Keith H Williamson; Lawrence E Armstrong Journal: Eur J Appl Physiol Date: 2015-01-22 Impact factor: 3.078
Authors: Juliette J Kahle; Lucas M Neas; Robert B Devlin; Martin W Case; Michael T Schmitt; Michael C Madden; David Diaz-Sanchez Journal: Environ Health Perspect Date: 2014-12-16 Impact factor: 9.031
Authors: Eurico N Wilhelm; José González-Alonso; Scott T Chiesa; Steven J Trangmar; Kameljit K Kalsi; Mark Rakobowchuk Journal: Physiol Rep Date: 2017-11
Authors: Sven Van Poucke; Dana Huskens; Kurt Van der Speeten; Mark Roest; Bart Lauwereins; Ming-Hua Zheng; Seppe Dehaene; Joris Penders; Abraham Marcus; Marcus Lancé Journal: PLoS One Date: 2018-06-21 Impact factor: 3.240